The economics of antimicrobial stewardship: The current state of the art and applying the business case model

Infection Control and Hospital Epidemiology

Volumn 33, Issue 4, 2012, Pages 389-397

  Stevenson, Kurt B ^a,b,c   Balada Llasat, Joan Miquel ^a   Bauer, Karri ^b   Deutscher, Meredith ^a,b   Goff, Debra ^b   Lustberg, Mark ^a,b   Pancholi, Preeti ^a   Reed, Erica ^b   Smeenk, David ^b   Taylor, Jeremy ^b   West, Jessica ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; COLISTIN; DAPTOMYCIN; DORIPENEM; FIDAXOMICIN; IMIPENEM; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP PROGRAM; COMMERCIAL PHENOMENA; DRUG COST; DRUG UTILIZATION; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; NOTE; PSEUDOMONAS INFECTION;

CROSS INFECTION; HOSPITAL ADMINISTRATION; HUMANS; INFECTION CONTROL;

EID: 84858809051     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/664910     Document Type: Note

References (54)

1. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011;52: 1232-1240.
2. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobialresistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996;275:234-240.
3. Goldmann DA, Huskins WC. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis 1997;24(suppl):S139-S145.
4. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-599.
5. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 2001;7:319-322.
6. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44: 159-177.
7. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033.
8. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989;23:441-451.
9. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-590.
10. Conus P, Francioli P. Relationship between ceftriaxone use and resistance of Enterobacter species. J Clin Pharm Ther 1992;17: 303-305.
11. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441-446.
12. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-1237.
13. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-888.
14. Muller AA, Mauny F, Bertin M, et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003;36:971-978.
15. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39:497-503.
16. Paterson DL, Ko WC, Von GA, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004;140:26-32.
17. Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 1988;157: 869-876.
18. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993;16:255-264.
19. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24:699-706.
20. LaRocco A Jr. Concurrent antibiotic review programs: a role for infectious diseases specialists at small community hospitals. Clin Infect Dis 2003;37:742-743.
21. Ansari F, Gray K, Nathwani D, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003;52:842-848.
22. Ruttimann S, Keck B, Hartmeier C, Maetzel A, Bucher HC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004;38:348-356.
23. Lutters M, Harbarth S, Janssens JP, et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 2004;52:112-116.
24. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-485.
25. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol 2007;28:1121-1133.
26. Stone PW. Methods for conducting and reporting cost-effectiveness analysis in nursing. Image J Nurs Sch 1998;30:229-234.
27. Lipworth AD, Hyle EP, Fishman NO, et al. Limiting the emergence of extended-spectrum b-lactamase-producing enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol 2006;27:279-286.
28. Fishman N. Antimicrobial stewardship. Am J Med 2006;119: S53-S61.
29. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(suppl 2):S112-S121.
30. Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med 2011;6(suppl 1):S4-S15.
31. Slain D, Sarwari AR, Petros KO, et al. Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting. Crit Care Res Pract 2011;2011:416-426.
32. Eddy DM. A Manual for Assessing Health Practices and Designing Health Policies. Philadelphia: The American College of Physicians, 1992.
33. Stone PW, Schackman BR, Neukermans CP, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis 2005;5:383-391.
34. Stone PW. Return-on-investment models. Appl Nurs Res 2005; 18:186-189.
35. Zilberberg MD, Shorr AF. Understanding cost-effectiveness. Clin Microbiol Infect 2010;16:1707-1712.
36. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006;21:402-408.
37. Scheetz MH, Bolon MK, Postelnick M, Noskin GA, Lee TA. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. J Antimicrob Chemother 2009;63:816-825.
38. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005;33:501-509.
39. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005;8:3-9.
40. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276: 1172-1177.
41. Gold MR, Siegel JE, Russell LB, and Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
42. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276: 1339-1341.
43. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1253-1258.
44. Ward WJ Jr, Spragens L, Smithson K. Building the business case for clinical quality. Healthc Financ Manage 2006;60:92-98.
45. Roberts RR, Frutos PW, Ciavarella GG, et al. Distribution of variable vs fixed costs of hospital care. JAMA 1999;281:644-649.
46. Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561-566.
47. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res 2009;9:417-422.
48. Eber MR, Laxminarayan R, Perencevich EN, Malani A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 2010;170:347-353.
49. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
50. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166-174.
51. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010;51:1074-1080.
52. Kamal J, Rogers P, Saltz J, Mekhjian H. Information warehouse as a tool to analyze computerized physician order entry order set utilization: opportunities for improvement. AMIA Annu Symp Proc 2003;336-340.
53. Schwartz DN, Evans RS, Camins BC, et al. Deriving measures of intensive care unit antimicrobial use from computerized pharmacy data: methods, validation, and overcoming barriers. Infect Control Hosp Epidemiol 2011;32:472-480.
54. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44: 357-363.